General Surgery Residency, Spectrum Health/Michigan State University, Grand Rapids, USA.
College of Human Medicine, Michigan State University, Grand Rapids, United States of America.
Interact Cardiovasc Thorac Surg. 2021 May 27;32(6):839-845. doi: 10.1093/icvts/ivab016.
The Magna Ease aortic valve (Edwards Lifesciences, Irvine, CA) is a third-generation bioprosthetic valve developed as a modification of the well-studied Perimount and Magna valve designs. This study's objective is to evaluate a large, single-centre experience with Magna Ease aortic valve replacement (AVR) focusing on clinical outcomes and haemodynamic performance.
All patients undergoing AVR between 8/2010 and 10/2018 at our institution implanted with the Magna Ease valve were included except those undergoing ventricular assist device or congenital aortic surgery. Primary outcomes were overall survival and freedom from reoperation. Mean transprosthetic gradient (mTPG) and structural valve deterioration (SVD) served as secondary outcomes.
Totally 1126 consecutive implantations of Magna Ease valves were included. Concomitant procedures were performed in 56.5% (n = 636). No severe patient-prosthesis mismatch (PPM) was present at implantation. Overall survival at 30 days, 1 year, 5 years and 9 years was 97.2%, 95.0%, 86.1% and 78.2%, respectively, with improved survival for isolated AVR. Total of 2.4% (n = 27) of patients required reoperation with 0.3% (n = 4) for SVD. Echocardiographic follow-up data revealed low mTPG throughout the study period. SVD occurred in 28.7% of patients at a mean of 3.9 years post implantation.
Magna Ease AVR maintained low mean transprosthetic gradients throughout mid-term evaluation and was associated with excellent overall survival and freedom from reoperation at nine years post implantation.
Magna Ease 主动脉瓣（爱德华生命科学公司，欧文，加利福尼亚州）是第三代生物瓣，是对经过充分研究的 Perimount 和 Magna 瓣膜设计的改良。本研究的目的是评估我们机构的一项大型、单中心的 Magna Ease 主动脉瓣置换术（AVR）经验，重点关注临床结果和血液动力学性能。
除了接受心室辅助装置或先天性主动脉手术的患者外，我们机构在 2010 年 8 月至 2018 年 10 月期间接受 Magna Ease 瓣膜植入的所有 AVR 患者均被纳入研究。主要结局是总生存率和免于再次手术。平均跨瓣梯度（mTPG）和结构性瓣膜退化（SVD）作为次要结局。
共纳入 1126 例连续植入 Magna Ease 瓣膜的患者。56.5%（n=636）的患者同时进行了其他手术。植入时无严重的患者-假体不匹配（PPM）。30 天、1 年、5 年和 9 年的总生存率分别为 97.2%、95.0%、86.1%和 78.2%，单纯 AVR 的生存率提高。共有 2.4%（n=27）的患者需要再次手术，其中 0.3%（n=4）为 SVD。整个研究期间的超声心动图随访数据显示 mTPG 较低。SVD 在植入后平均 3.9 年发生在 28.7%的患者中。
Magna Ease AVR 在中期评估中保持较低的平均跨瓣梯度，与植入后 9 年的总生存率和免于再次手术率优异相关。
